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Prenatal exposures to phthalates and perfluori­
nated compounds (PFCs) are suspected to 
cause immediate and long­term adverse 
health effects in the offspring (Jurewicz and 
Hanke 2011; Lau et al. 2007; Matsumoto 
et al. 2008; Olsen et al. 2009). Exposures are 
ubiquitous and well documented in pregnant 
women (Adibi et al. 2003; Fromme et al. 
2009; Woodruff et al. 2011; Yan et al. 2009). 
Direct fetal exposure, however, is less easily 
determined (Arbuckle 2010). Measurements 
in blood or urine from pregnant women 
may serve as proxies, but correlations with 
measures in fetal compartments can be 
low (Huang et al. 2009; Latini et al. 2003; 
Wittassek et al. 2009). Placental transfer of 
phthalates and PFCs has been documented in 
rodents (Calafat et al. 2006; Yu et al. 2009) 
and humans (Inoue et al. 2004; Latini et al. 
2003). Human ex vivo placental perfusion 
studies generally suggested lower phthalate 
levels in the fetal circulation than in the mater­
nal circulation (Mose et al. 2007a, 2007b). 
Paired measurements have suggested either 
identical or lower phthalate levels in fetal cord 
blood compared with maternal blood (Chen 
et al. 2008; Latini et al. 2003; Yan et al. 2009; 
Zhang et al. 2009) and generally lower fetal 
levels of PFCs (Fromme et al. 2009, 2010; 
Hanssen et al. 2010; Monroy et al. 2008). 
In practice, cord blood is obtainable only at 
birth, but the expected vulnerable time win­
dow for many health outcomes is often earlier 
in pregnancy (e.g., during organogenesis).
Amniotic fluid offers another possible 
fetal matrix, but samples are most often avail­
able only from amniocentesis indicated by 
advanced maternal age or by prenatal diag­
nostics of chromosomal abnormalities and 
severe malformations. Another challenge, 
which is not unique to amniotic fluid (Sibai 
and Frangieh 1995), is the dynamic changes 
in amniotic fluid volume and composition 
throughout pregnancy (Benzie et al. 1974; 
Brace 1997; Modena and Fieni 2004), which 
complicate interpretation of measured pol­
lutant concentrations. One major advan­
tage, however, is that amniocentesis usually 
is performed within the second trimester, 
which for many outcomes may be closer to 
the expected vulnerable period. This may be 
more important for the short­lived phthalate 
metabolites than for the persisting PFCs (Lau 
et al. 2007; Wittassek and Angerer 2008). 
Only three studies comprising a total of 129 
samples have reported phthalate metabolites 
in human amniotic fluid (Huang et al. 2009; 
Silva et al. 2004; Wittassek et al. 2009), and 
to the best of our knowledge, no published 
studies have reported measures of PFCs in 
human amniotic fluid. The scarce nature of 
such measurements limits our knowledge 
about exposure levels, kinetics, metabolism 
and elimination. Further, none of the pre­
vious studies have been able to investigate 
temporal exposure trends or potential asso­
ciations with important covariates such as 
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Ba c k g r o u n d: Measures of prenatal environmental exposures are important, and amniotic fluid 
levels may directly reflect fetal exposures during hypothesized windows of vulnerability.
oBjectives: We aimed to detect various phthalate metabolites and perfluorooctanesulfonic acid 
(PFOS) in human amniotic fluid, to study temporal exposure trends, and to estimate potential asso-
ciations with gestational week of amniocentesis and maternal age and parity at amniocentesis.
Me t h o d s : We studied 300 randomly selected second-trimester amniotic fluid samples from a 
Danish pregnancy-screening biobank covering 1980 through 1996. We used only samples from 
male offspring pregnancies. We assayed the environmental pollutants by liquid chromatography/
triple quadrupole mass spectrometry and analyzed data using generalized linear regression models.
re s u l t s: We detected the di(2-ethylhexyl) phthalate (DEHP) metabolite mono(2-ethyl-5-carboxy-
pentyl) phthalate (5cx-MEPP) at a median concentration of 0.27 ng/mL [interquartile range (IQR): 
0.20–0.37 ng/mL], the diisononyl phthalate (DiNP) metabolite mono(4-methyl-7-carboxyheptyl) 
phthalate (7cx-MMeHP) at 0.07 ng/mL (IQR: 0.05–0.11 ng/mL), and PFOS at 1.1 ng/mL (IQR: 
0.66–1.60 ng/mL). An increase of 1 calendar year was associated with 3.5% lower [95% confidence 
interval (CI): –4.8%, –2.1%] 5cx-MEPP levels and with 7.1% higher (95% CI: 5.3%, 9.0%) 
7cx-MMeHP levels. For each later gestational week of amniocentesis, 5cx-MEPP was 9.9% higher 
(95% CI: 4.8%, 15.2%), 7cx-MMeHP was 8.6% higher (95: CI: 2.7%, 14.9%), and PFOS was 
9.4% higher (95: CI: 3.3%, 15.9%). We observed no associations with maternal age or parity.
co n c l u s i o n s: Measured metabolite levels appeared to parallel decreasing DEHP exposure and 
increasing DiNP exposure during the study period. The environmental pollutant levels were posi-
tively associated with later gestational age at amniocentesis during pregnancy weeks 12–22.
key w o r d s : amniocentesis, amniotic fluid, biobank, biomonitoring, perfluorinated compounds, 
phthalates, pregnancy, temporal trend. Environ Health Perspect 120:897–903 (2012).  http://
dx.doi.org/10.1289/ehp.1104522 [Online 7 March 2012]Jensen et al.
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gestational age, maternal parity, and maternal 
age at amniocentesis.
We aimed to describe levels of phthalate 
metabolites and perfluorooctanesulfonic acid 
(PFOS) in human amniotic fluid samples 
from a Danish biobank. In addition, we inves­
tigated temporal trends in exposure levels, as 
well as potential associations with gestational 
age, maternal age, and parity at amniocentesis.
Methods
Study population and amniotic fluid   samples. 
We used amniotic fluid samples from a 
Danish biobank maintained at the State 
Serum Institute in Copenhagen. The biobank 
holds samples from a pregnancy screening 
registry including both amniotic fluid and 
maternal serum samples from > 100,000 preg­
nancies covering the period 1979 through 
2004 (amniotic fluid samples 1980–1996). 
The amniotic fluid samples were centrifuged 
before routine diagnostic analyses and the 
supernatants were kept frozen at –20°C until 
the present analyses were carried out. The sam­
ples were from Sealand (Copenhagen hospitals 
and Hillerød Hospital) and from Southern 
Jutland (Sønderborg and Kolding Hospitals). 
The main indication for amniocentesis was 
age ≥ 35 years, but some samples were from 
women with increased risk of severe malfor­
mations or Down syndrome based on results 
from maternal serum analyses.
Each mother’s personal identification 
number (unique to each Danish citizen) was 
recorded in the pregnancy screening registry 
and also identified her amniotic fluid sample. 
We used the unique identifiers of all women 
in the pregnancy screening registry to obtain 
obstetric data on all their pregnancies from 
the Danish Medical Birth Registry (Knudsen 
and Olsen 1998), including gestational age 
at birth, singleton or multiple birth, maternal 
parity, and birth weight and Apgar score of 
the infant. In addition, we used the unique 
identifiers in the Danish Civil Registration 
System to identify each mother’s children 
(Pedersen et al. 2006). We included only live­
born boys because this study was part of a 
larger study on male urogenital anomalies. 
To verify that the amniotic fluid sample and 
the identified boy originated from the same 
pregnancy, we selected only those where the 
amniocentesis had been performed between 
10 and 30 weeks from the estimated date of 
conception, defined by subtracting the ges­
tational age at birth from the date of birth. 
We then followed the identified boys in 
the Danish National Patient Registry until 
November 2008 to obtain records of urogeni­
tal anomalies and other congenital malforma­
tions, including chromosomal abnormalities 
[International Classification of Diseases, 8th 
Revision (ICD­8; World Health Organization 
1969), codes 74000–75999; ICD­10 (10th 
Revision; World Health Organization 1993) 
codes Q00–Q99] (Andersen et al. 1999). 
We selected a random sample for this study 
among all live­born singleton boys born to 
women registered in the pregnancy­screening 
registry and with complete obstetric data.
The gestational age at birth was deter­
mined by last menstrual period and corrected 
by ultrasound according to local guidelines 
if necessary. Obstetric ultrasound became 
increasingly available in Denmark during the 
study period and was performed on approxi­
mately 93% of all pregnant women by 1995 
(Jørgensen 1999). We calculated gestational 
week of amniocentesis as the distance between 
the estimated date of conception (defined 
above) and the date of amniocentesis.
The Danish Regional Ethics Committee, 
the Danish National Board of Health, and 
the Danish Data Protection Agency approved 
the study. The use of the biobank for research 
purposes has been approved, and additional 
informed consent from the study subjects for 
this specific project was neither recommended 
nor required.
Chemical analysis.  We assayed the 
di(2­ethylhexyl) phthalate (DEHP) metabo­
lites mono(2­ethyl­5­hydroxylhexyl) phthalate 
(5OH­MEHP), mono(2­ethyl­5­oxohexyl) 
phthalate (5oxo­MEHP), and mono(2­ethyl­
5­carboxypentyl) phthalate (5cx­MEPP) and 
the diisononyl phthalate (DiNP) metabo­
lites  mono(4­methyl­7­hydroxyoctyl) 
phthalate (7OH­MMeOP), mono(4­methyl­
7­oxooctyl) phthalate (7oxo­MMeOP), and 
mono(4­  methyl­7­carboxyheptyl) phthalate 
(7cx­MMeHP), as well as PFOS and cotinine, 
in the amniotic fluid samples during the sum­
mer and fall of 2010. We detected 5cx­MEPP, 
7cx­MMeHP, PFOS, and cotinine, and the 
method had good reproducibility as determined 
from duplicate samples analyzed at different 
days. Coefficients of variation were between 9% 
and 16%, and we achieved rather low limits of 
detection (LOD), which were determined as the 
concentrations corresponding to three times the 
standard deviation of the responses in chemi­
cal blanks [for more details, see Supplemental 
Material, Table S1 (http://dx.doi.org/10.1289/
ehp.1104522)]. We monitored the quality 
by analyzing chemical blanks and in­house 
  quality­control samples in all batches.
We added 10 μL 1 M ammonia acetate 
and 10 μL glucoronidase from Escherichia coli 
to aliquots of 100 μL amniotic fluid. After 
mixing, we incubated the samples at 37°C for 
90 min. We prepared standards from amniotic 
fluid added with known amounts of phthalate 
metabolites, PFOS, and cotinine in 25 μL of a 
50:50 solution of water and acetonitrile. We 
added 25 μL of the same solution but without 
the compounds to the samples, and then added 
25­μL aliquots of a 50:50 water:acetonitrile 
solution of 13C­ and 2H­labeled internal 
standards for all analyzed compounds. We 
precipitated the proteins by adding 150 μL 
acetonitrile and vigorously shaking for 30 min, 
and afterward we centrifuged the samples and 
transferred them to autosampler vials.
We analyzed the samples using a liq­
uid chromatograph (LC; model UFLCXR, 
Shimadzu Corp., Kyoto, Japan). In the analy­
sis of the phthalates, we injected aliquots of 
5 μL on a C18 column (4 μm, 2.1 mm inner 
diameter × 50 mm GENISIS; Grace Vydac, 
Hesperia, CA, USA). The mobile phases 
consisted of 0.08% formic acid in water and 
acetonitrile. The separation started at 20% 
acetonitrile, followed by a linear gradient of 
acetonitrile to 75% in 3 min. We washed the 
column by 95% acetonitrile and then equili­
brated in 20% acetonitrile during 2 min. In the 
analysis of PFOS, we injected aliquots of 3 μL 
on a C18 column (4 μm, 2.1 mm inner diam­
eter × 50 mm GENISIS). The mobile phases 
consisted of 0.1% ammonia in water and ace­
tonitrile. The separation started with a 5­min 
isocratic step at 30% acetonitrile, followed by a 
linear gradient of acetonitrile to 95% in 2 min. 
We then equilibrated the column in 30% ace­
tonitrile for 2 min. In the analysis of cotinine, 
we injected aliquots of 3 μL on a C18 Hypersil 
GOLD column (5 μm, 3 mm inner diam­
eter × 150 mm; Thermo Scientific, Waltham, 
MA, USA). The mobile phases consisted of 
0.1% ammonia in water and acetonitrile. The 
separation started with a 1­min isocratic step 
at 25% acetonitrile, followed by a linear gradi­
ent of acetonitrile to 95% for 3 min. We then 
equilibrated the column in 25% acetonitrile 
for 2 min. The LC was connected to a hybrid 
triple quadrupole linear ion trap tandem mass 
spectrometer (LC/MS/MS) equipped with a 
turbo ion spray source (QTRAP 5500; AB 
Sciex, Foster City, CA, USA). For technical 
parameters and for sample chromatograms, 
see Supplemental Material, Table S2 and 
Figures S1, S2 (http://dx.doi.org/10.1289/
ehp.1104522).
Recent participation in interlaboratory 
urine sample control programs of several phtha­
late metabolites, including 5cx­MEPP and 
7cx­MMeHP, and of cotinine yielded results 
good enough for the laboratory to become a ref­
erence laboratory in a large European biomoni­
toring program [Consortium to Perform Human 
Biomonitoring on a European Scale (COPHES) 
2012]. Furthermore, the laboratory’s analy­
ses of PFOS in serum and of 5cx­MEPP and 
cotinine in urine are part of the Round Robin 
intercomparison program (H. Drexler, Institute 
and Out­Patient Clinic for Occupational, Social 
and Environmental Medicine, University of 
Erlangen­Nuremberg, Germany), with results 
within the tolerance limits.
Statistical analysis. We compared preg­
nancy characteristics by amniotic fluid sample 
availability to evaluate potential selection bias. Phthalates and PFOS in human amniotic fluid
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We tabulated proportions or means and used 
Pearson’s chi­square test for categorical vari­
ables and the t­test for continuous variables 
when comparing the groups.
Less than 5% of the values from the 
chemical assays of the four detected envi­
ronmental pollutants were below the LOD, 
and they were imputed with a random value 
between LOD and LOD/2. For each pol­
lutant we present the LOD, the proportion 
of samples above LOD and the 10th, 25th, 
50th, 75th, and 100th percentiles.
We estimated potential associations of cal­
endar year, gestational age, and maternal age 
and parity at amniocentesis with each pol­
lutant in generalized linear regression models 
with squared terms of the numerical explana­
tory variables to estimate deviations from lin­
earity. We transformed the environmental 
pollutant measures by the natural logarithm 
(ln) to normalize the distribution of residuals, 
and we consequently exponentiated the differ­
ences estimated on the ln scale to obtain ratios 
of the medians. We present these ratios as 
crude and adjusted percent change per unit of 
the explanatory variable with 95% confidence 
intervals (CIs). In addition, we present associa­
tions with the numerical explanatory variables 
as scatter plots with unadjusted linear regres­
sion lines. We made mutual adjustments for 
calendar year of amniocentesis (1980–1984, 
1985–1990, 1991–1996), gestational age at 
amniocentesis (< 15, 15–17, ≥ 17 weeks), 
maternal age at amniocentesis (< 30, 30–34, 
≥ 35 years), maternal smoking estimated by 
cotinine levels [“non  smoker” < 25, “passive 
smoker” 25–85, “active smoker” ≥ 85 ng/mL 
amniotic fluid (Jauniaux et al. 1999)], and 
maternal parity (0, 1, ≥ 2 prior births). We 
estimated correlation coefficients between the 
ln­transformed environmental pollutants with 
p­values from Spearman rank correlations. All 
p­values were estimated by two­tailed tests, 
and we considered an α­level of 0.05 statisti­
cally significant. Statistical analyses were per­
formed using STATA software (version 11; 
StataCorp, College Station, TX, USA).
Results
The pregnancy screening registry had records 
of 63,882 amniotic fluid samples (Figure 1). 
After restriction to live­born singleton boys 
with complete obstetric data, 25,105 preg­
nancies were eligible. We selected a ran­
dom sample of 412 for this study, of which 
20 amniotic fluid samples were not located in 
the biobank and 92 samples had insufficient 
volume, leaving 300 samples (73%) available 
for chemical analyses.
We compared pregnancy characteristics by 
availability of amniotic fluid samples (Table 1). 
Mothers with unavailable samples were older 
and more likely to have had their amnio­
centesis between 1985 and 1990. Differences 
by availability were indicated for maternal par­
ity and prevalence of congenital malforma­
tions. Other characteristics, such as gestational 
week of amniocentesis, boys’ Apgar score, ges­
tational age at birth, and birth weight, did not 
differ between the two groups.
The two detected phthalate metabolites, 
PFOS, and cotinine were all assayed with 
> 95% above the LOD (Table 2). Medians 
were 0.27 ng/mL [interquartile range 
(IQR): 0.20–0.37 ng/mL] for the DEHP 
metabolite 5cx­MEPP, 0.07 ng/mL (IQR: 
0.05–0.11 ng/mL) for the DiNP metabolite 
7cx­MMeHP, 1.1 ng/mL (IQR: 0.66–1.60 
ng/mL) for PFOS, and 2.2 ng/mL (IQR: 
0.60–144 ng/mL) for cotinine. We estimated 
a correlation coefficient of 0.16 (p < 0.01) 
between 5cx­MEPP and 7cx­MMeHP, 0.17 
(p = 0.03) between 7cx­MMeHP and PFOS, 
and 0.18 (p < 0.01) between 5cx­MEPP and 
PFOS. Maternal smoking (non  smoker, pas­
sive smoker, active smoker) was not associated 
with gestational age at amniocentesis (< 15, 
15–17, ≥ 17 weeks) in a 3 × 3 contingency 
table (Pearson chi­square p = 0.69).
After adjustment, an increase of 1 cal­
endar year was associated with 3.5% lower 
5cx­MEPP levels (95% CI: –4.8%, –2.1%), 
with 7.1% higher 7cx­MMeHP levels (95% 
CI: 5.3%, 9.0%), and with 1.5% higher 
PFOS levels (95% CI: –0.3%, 3.2%) 
(Figure 2, top row; Table 3). 5cx­MEPP, 
7cx­MMeHP, and PFOS levels were approxi­
mately 8–10% higher for each later gesta­
tional week of amniocentesis (Figure 2, 
Table 1. Pregnancy and offspring characteristics of 412 randomly selected amniotic fluid samples, by 
availability, Denmark, 1980–1996.
Amniotic fluid samples (n = 412)
Characteristic Available (n = 300) Unavailable (n = 112) p-Valuea
Maternal age at birth [years (%)] 0.02
< 30 30 21
30–34 24 17
≥ 35 46 62
Primiparous (%) 35 28 0.14
Year of amniocentesis (%) < 0.001
1980–1984 33 20
1985–1990 34 60
1991–1996 33 20
Gestational week of amniocentesis (%) 0.78
< 15 27 23
15–17 57 60
≥ 17 16 17
Congenital malformations in boysb (%) 6 11 0.13
Apgar score ≥ 9 (%) 85 84 0.88
Gestational age at birth [weeks (mean ± SD)] 39.6 ± 1.5 39.5 ± 1.8 0.79
Birth weight [g (mean ± SD)] 3,535 ± 561 3,544 ± 664 0.89
aCategorical variables were tested with Pearson’s chi-square test, and continuous variables with the t-test. 
  bCryptorchidism and hypospadias were not included.
Figure 1. Study population and amniotic fluid 
  samples, Denmark, 1980–1996.
Danish amniotic ﬂuid sample biobank (n = 63,882)
Pregnancy offspring: female, not alive, 
or multiples (n = 37,647)
Live-born males with incomplete obstetric
data (n = 1,130)
Live-born singleton males with obstetric data 
(n = 25,105)
Random sample (n = 412)
20 samples not located (5%)
92 samples with insufﬁcient volume (22%)
300 samples available for analysis (73%)
Table 2. Amniotic fluid concentrations of detected phthalate metabolites, PFOS and cotinine, Denmark, 
1980–1996 (n = 300).
Environmental 
pollutant
Percentile (ng/mL)
LOD (ng/mL) n (%) ≥ LOD 10th 25th 50th 75th 90th Maximum
5cx-MEPP 0.05 296 (99) 0.16 0.20 0.27 0.37 0.51 2.3
7cx-MMeHP 0.02 288 (96) 0.02 0.05 0.07 0.11 0.15 0.91
PFOS 0.2 295 (98) 0.43 0.66 1.1 1.6 2.0 4.5
Cotinine 0.2 293 (98) 0.30 0.60 2.2 144 263 531Jensen et al.
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middle row; Table 3). These trends were 
slightly stronger for all pollutants in the most 
recent years (1991–1996; data not shown). 
We observed statistically significant devia­
tions from linearity for two associations: 
The association between year of amniocen­
tesis and 7cx­MMeHP had a very slight 
curvature that would not invalidate conclu­
sions from a linear model; the association 
between gestational week of amniocentesis 
and PFOS had a stronger curvature that was 
driven by the five imputed values below the 
LOD [the non  linearity was removed after 
exclusion of these observations; for details 
on these nonlinearities, see Supplemental 
Material, Figures S3 and S4 (http://dx.doi.
org/10.1289/ehp.1104522)]. None of the 
environmental pollutants were associated with 
maternal age (Figure 2, bottom row; Table 3) 
or consistently associated with maternal parity 
(Table 4).
Figure 2. Amniotic fluid 5cx-MEPP (left column), 7cx-MMeHP (middle column) and PFOS (right column) according to year of amniocentesis (top row), gestational 
week of amniocentesis (middle row), and maternal age at amniocentesis (bottom row): Denmark, 1980–1996. The y-axis scale is natural logarithm (ln). Solid lines 
are unadjusted linear regressions; dotted lines are LODs for each environmental pollutant. 
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Year of amniocentesis
Gestational week of amniocentesis
Maternal age at amniocentesis (years) Maternal age at amniocentesis (years) Maternal age at amniocentesis (years)
Gestational week of amniocentesis Gestational week of amniocentesis
Year of amniocentesis Year of amniocentesis
Table 3. Percent change (95% CI) in amniotic fluid environmental pollutant concentration by one unit increase in calendar year of amniocentesis (1980–1996), 
gestational week of amniocentesis (12–22), and maternal age at amniocentesis (17–44 years).
Percent changea
Environmental 
pollutant
Per calendar year Per gestational week Per year of maternal age
Crude Adjusted (95% CI)b Crude Adjusted (95% CI)c Crude Adjusted (95% CI)d
5cx-MEPP –3.4 –3.5 (–4.8, –2.1) 12.5 9.9 (4.8, 15.2) –1.1 –0.6 (–1.9, 0.8)
7cx-MMeHP 7.1 7.1 (5.3, 9.0) 3.5 8.6 (2.7, 14.9) –0.6 0.5 (–1.0, 2.1)
PFOS 1.1 1.5 (–0.3, 3.2) 8.4 9.4 (3.3, 15.9) 0.1 0.4 (–1.2, 2.0)
aThe ratio of medians estimated by linear regression with the pollutant concentration on the ln scale. bAdjusted for maternal smoking, parity, gestational age at amniocentesis, and 
maternal age. cAdjusted for maternal smoking, parity, year of amniocentesis, and maternal age. dAdjusted for maternal smoking, parity, year of amniocentesis, and gestational age at 
amniocentesis.Phthalates and PFOS in human amniotic fluid
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Discussion
We studied the concentrations of phthalate 
metabolites and PFOS in the largest set of 
human amniotic fluid samples reported so far. 
We were able to detect one DEHP metabo­
lite (5cx­MEPP), one DiNP metabolite 
(7cx­MMeHP), and PFOS. Concentrations 
of these environmental pollutants were low, 
and correlations between them were incon­
sequential. We observed metabolite levels 
suggesting decreasing DEHP exposure and 
increasing DiNP exposure during the study 
period of 1980–1996.
Our cross­sectional data suggested higher 
levels of all three environmental pollutants 
for each later gestational week of amnio­
centesis during weeks 12–22. This trend of 
higher concentrations in later weeks coin­
cides with increasing fetal urine excretion and 
amniotic fluid volume expansion (Gilbert 
and Brace 1993; Lotgering and Wallenburg 
1986). The phthalate metabolites and PFCs 
are to some extent protein bound, and the 
total protein concentration in amniotic fluid 
also increases during weeks 12–22 (Griffiths 
et al. 1988; Jauniaux et al. 1994; Jones et al. 
2003; Queenan 1978). Although these physi­
ological changes might account for part of 
the associations, it is probably premature to 
fully explain these identical trends in various 
environmental pollutants with different half­
lives (Lau et al. 2007; Wittassek and Angerer 
2008). However, the findings do underscore 
the importance of including gestational age 
at amniocentesis in statistical analyses of envi­
ronmental pollutant levels in amniotic fluid.
Gestational age determination has inher­
ent limitations, but any random misclassifica­
tion would most likely attenuate the observed 
positive associations with levels of the envi­
ronmental pollutants. Theoretically, the asso­
ciations could be produced by mothers with 
high environmental pollutant levels (or life­
styles associated with high levels) having their 
amniocentesis later, due to, for example, later 
recognition of pregnancy. We observed no 
association between amniotic fluid cotinine 
levels (maternal smoking) and gestational week 
at amniocentesis, which is reassuring regarding 
this potential bias mechanism. Another sys­
tematic error could occur if high levels of the 
environmental pollutants are associated with 
irregular menstrual cycle (Fei et al. 2009). This 
would only affect gestational age determined 
by last menstrual period, which was most fre­
quent in the first part of the study period. The 
association with gestational week of amnio­
centesis was slightly stronger for all pollutants 
in the most recent years (1991–1996). During 
this period, approximately 90% of Danish 
pregnant women had an obstetric ultrasound 
free of charge (Jørgensen 1999), which would 
tend to reduce this possible bias (if present). 
It would, however, require replication by 
paired within­person measurements during 
pregnancy to draw definitive conclusions of 
a genuine increase in pollutant levels during 
weeks 12–22.
Several DEHP and DiNP metabolites 
have been detected in human amniotic fluid 
from Taiwan during 2005–2006 (Huang et al. 
2009) and from the United States (Silva et al. 
2004) and Germany (Wittassek et al. 2009) 
during undescribed time periods (Table 5). 
Mono(2­ethylhexyl) phthalate (MEHP) lev­
els were reported > 10 times higher in Taiwan 
(22.1 ng/mL; Huang et al. 2009) than in 
Germany (1.6 ng/mL; Wittasek et al. 2009). 
Human placental perfusion studies have 
shown no or very low transfer of MEHP to 
fetal compartments (Mose et al. 2007a, 
2007b), and whether the reported amniotic 
fluid MEHP levels reflect true geographical 
differences in exposure, varying laboratory 
methods, or contamination remains a puzzle. 
Some measures were taken to avoid contami­
nation in the Taiwanese study (Huang et al. 
2009), but amniotic fluid may have lipase 
or esterase activity that hydrolyses phthalate 
diesters to monoesters. Thus, if monoesters 
are the analytic goal, samples must be acidi­
fied immediately after amniocentesis (which 
was not done) to avoid enzyme activity. Unlike 
with monoesters, the secondary metabolites are 
unlikely subjects of contamination (Wittassek 
and Angerer 2008). Among secondary DEHP 
metabolites the   carboxy­metabolites 5cx­MEPP 
and mono(2­carboxy­hexyl) phthalate 
(2cx­MMHP) have been most readily detected 
(Table 5). 5cx­MEPP was measured within 
the same range of magnitude in Germany 
(Wittasek et al. 2009) and Denmark (pres­
ent study). Among secondary DiNP metabo­
lites, the German study (Wittasek et al. 2009) 
detected 7cx­MMeHP in only 1 of 11 samples 
but at a rather high level of 4.9 ng/mL. We 
detected 7cx­MMeHP in 96% of the samples 
in our study with a lower LOD. 7cx­MMeHP 
and 5cx­MEPP are major urinary metabolites of 
DiNP and DEHP respectively (Jönsson BAG, 
unpublished data; Silva et al. 2006). Hence, it 
is not surprising that these metabolites were also 
Table 4. Environmental pollutant concentration in amniotic fluid according to maternal parity at amniocentesis, Denmark, 1980–1996.
5cx-MEPP 7cx-MMeHP PFOS
Parity n
Mean 
(ng/mL)
Median 
(ng/mL)
Percent change 
(95% CI)a p-Valueb
Mean 
(ng/mL)
Median 
(ng/mL)
Percent change 
(95% CI)a p-Valueb
Mean 
(ng/mL)
Median 
(ng/mL)
Percent change 
(95% CI)a p-Valueb
0 106 0.32 0.26 0.09 0.07 1.21 1.08
1 93 0.35 0.26 9.4 (–6.5, 28.1) 0.82 0.10 0.08 21.8 (1.2, 46.6) 0.06 1.23 1.03 –2.5 (–19.4, 17.9) 0.76
≥ 2 101 0.30 0.27 –4.3 (–18.8, 12.9) 0.64 0.08 0.06 –5.6 (–22.3, 14.5) 0.17 1.18 1.09 –2.2 (–19.8, 19.3) 0.84
aThe ratio of medians estimated by linear regression with the pollutant concentration on the ln scale and adjusted for year of amniocentesis, gestational age at amniocentesis, mater-
nal age, and maternal smoking. Reference group is nullipara. bWilcoxon rank-sum test with nullipara as reference group.
Table 5. DEHP and DiNP metabolites currently detected by MS in human amniotic fluid.
Metabolite Studya Detected LOD (ng/mL) Median (ng/mL)
DEHP
MEHP 1 (+) 0.86 < LOD
2 + 0.90 22.10
3 + 0.15 1.60
5OH-MEHP 1 – — —
3 (+) 0.15 < LOD
4 – 0.10 —
5oxo-MEHP 1 – — —
3 (+) 0.15 < LOD
4 – 0.03 —
5cx-MEPP 3 + 0.15 0.53
4 + 0.05 0.27
2cx-MMHP 3 + 0.15 0.64
DiNP
Monoisononyl phthalate 1 – — —
7OH-MMeOP 3 – 0.15 —
4 – 0.01 —
7oxo-MMeOP 3 – 0.15 —
4 – 0.02 —
7cx-MMeHP 3  (–)b 0.15 —
4 + 0.02 0.07
Symbols: – not detected, (+) poorly detected (median below LOD), + detected, — not available. 
aStudies: 1, Silva et al. (2004), United States; 2, Huang et al. (2009), Taiwan; 3, Wittassek et al. (2009), Germany; 4, present 
study, Denmark. b7cx-MMeHP was detected in only 1 of 11 samples.Jensen et al.
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detected in amniotic fluid and that others were 
below LODs. In addition, 5cx­MEPP has a lon­
ger half­life in urine than do 5OH­MEHP and 
5oxo­MEHP (Heudorf et al. 2007), thus mak­
ing 5cx­MEPP a more stable urine biomarker of 
DEHP exposure. Based on this, 5cx­MEPP and 
7cx­MMeHP may also likely be the most stable 
DEHP and DiNP biomarkers in amniotic fluid 
if elimination patterns compare with urine. 
DiNP is a widely used modern phthalate that 
has to some extent replaced DEHP (Wittassek 
et al. 2007). For this reason, it is important to 
develop methods to measure DiNP metabo­
lites for exposure biomonitoring and etiologi­
cal research purposes. Furthermore, this study 
provides the first published detection of PFOS, 
another important environmental pollutant, in 
human   amniotic fluid.
A few studies reported temporal trends in 
exposures to phthalates and PFCs in Denmark’s 
neighbor countries. A study from Germany 
estimated daily phthalate intake based on 
24­hr urinary metabolite excretion in 634 stu­
dents 20–29 years of age during 1988–2003 
(Wittassek et al. 2007). Data strongly suggested 
a decrease in DEHP exposure and an increase 
in DiNP exposure over time, which is exactly 
what we observed during the years 1980–1996 
(Figure 2, top row). PFOS exposure trends 
were considerably more heterogeneous; a study 
from Norway using pooled serum samples 
reported an increase in young females’ PFOS 
levels from 2.5 ng/mL in 1976 to 25 ng/mL in 
1998 (Haug et al. 2009), but during almost the 
same period we observed a very limited increase, 
with CIs including no change (Figure 2, top 
row). A small study from Germany observed 
an increase in young students’ plasma PFOS 
levels from 10 ng/mL in 1977 to 26 ng/mL 
in 1990 (based on 18 samples) (Wilhelm et al. 
2009). However, a decline in PFOS levels in 
German students was reported from 1985 
to 2004, partly covering the same period 
(Wiesmuller et al. 2007). Hence, data on PFOS 
time trends remain rather inconsistent in these 
comparable populations.
We used samples from a large pregnancy­
screening biobank. The main indication for 
amniocentesis was ≥ 35 years of age (46% of 
mothers; Table 1), but samples were also from 
women with increased risk of severe malfor­
mations or Down syndrome based on results 
from maternal serum analyses. Selective par­
ticipation in the pregnancy­screening pro­
gram remains a theoretic possibility, but the 
screening was offered to all eligible women by 
their family doctor or obstetrician and free of 
charge. We selected a random sample from 
the database, but approximately 27% of that 
sample was not available because of missing 
amniotic fluid samples or insufficient vol­
ume (Figure 1). Several characteristics, such 
as gestational week of amniocentesis, boys’ 
Apgar score, gestational age at birth, and birth 
weight, did not differ by availability. Available 
samples were evenly distributed across calen­
dar years, whereas unavailable samples were 
more often from the middle of the study 
period (Table 1). Mothers with available 
samples were younger, and we speculate that 
the obtained volume by amniocentesis or the 
analytical volume needed may differ between 
routine screening assays (age ≥ 35 years) and 
assays because of suspected pathology (age 
more frequently < 35 years). It remains diffi­
cult, however, to understand why selection by 
remaining volume would bias our findings.
We performed the chemical analyses 
blinded to all other information, and we 
randomized the samples before analyses. The 
levels of environmental pollutants were very 
low, especially for the phthalate metabolites. 
We used a newly developed, simple, and 
rapid workup method for the determinations, 
requiring only very low sample volume and 
using the latest generation of highly sensitive 
LC/MS/MS equipment. The achieved LODs 
were generally much lower than for previously 
described methods (Huang et al. 2009; Silva 
et al. 2004; Wittassek et al. 2009), although 
the imprecision might increase at the lowest 
levels. The choice of imputation procedure 
for the < 5% of samples below LOD is not 
expected to impact our findings.
Our data were based only on male off­
spring pregnancies and might not be represen­
tative for female offspring pregnancies if they 
have different fetal or maternal metabolism or 
excretion (Kudo and Kawashima 2003; Lau 
et al. 2004). However, recent evidence sug­
gests no sex differences in renal excretion of 
PFCs in humans (Harada et al. 2005), and 
comparable levels in both sexers have been 
observed for several phthalate metabolites 
(Huang et al. 2009).
Conclusion
We detected one DEHP metabolite, one DiNP 
metabolite, and PFOS in human amniotic fluid. 
Other assayed phthalate metabolites were below 
LODs. Measured metabolite levels appeared to 
parallel decreasing DEHP exposure and increas­
ing DiNP exposure during the study period of 
1980–1996. Further, we observed positive asso­
ciations between levels of the three measured 
environmental pollutants and gestational age 
at amniocentesis during weeks 12–22. Levels 
of the pollutants in amniotic fluid were not 
  associated with maternal age or parity.
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